Abstract
Background Patient-specific quality assurance (PSQA) is part of the standard practice to ensure that a patient receives the dose from intensity-modulated radiotherapy (IMRT) beams as planned in the treatment planning system (TPS). PSQA failures can cause a delay in patient care and increase workload and stress of staff members. A large body of previous work for PSQA failure prediction focuses on non-learned plan complexity measures. Another prominent line of work uses machine learning methods, often in conjunction with feature engineering. Currently, there are no machine learning solutions which work directly with multi-leaf collimator (MLC) leaf positions, providing an opportunity to improve leaf sequencing algorithms using these techniques.
Purpose To improve patient safety and work efficiency, we develop a tabular transformer model based directly on the MLC leaf positions (without any feature engineering) to predict IMRT PSQA failure. This neural model provides an end-to-end differentiable map from MLC leaf positions to the probability of PSQA plan failure, which could be useful for regularizing gradient-based leaf sequencing optimization algorithms and generating a plan that is more likely to pass PSQA.
Method We retrospectively collected DICOM RT PLAN files of 968 patient plans treated with volumetric arc therapy. We construct a beam-level tabular dataset with 1873 beams as samples and MLC leaf positions as features. We train an attention-based neural network FT-Transformer to predict the ArcCheck-based PSQA gamma pass rates. In addition to the regression task, we evaluate the model in the binary classification context predicting the pass or fail of PSQA. The performance was compared to the results of the two leading tree ensemble methods (CatBoost and XGBoost) and a non-learned method based on mean MLC gap.
Results The FT-Transformer model achieves 1.44% Mean Absolute Error (MAE) in the regression task of the gamma pass rate prediction and performs on par with XGBoost (1.53 % MAE) and CatBoost (1.40 % MAE). In the binary classification task of PSQA failure prediction, FT-Transformer achieves 0.85 ROC AUC (with CatBoost and XGBoost achieving 0.87 ROC AUC and the mean-MLC-gap complexity metric achieving 0.72 ROC AUC). Moreover, FT-Transformer, CatBoost, and XGBoost all achieve 80% true positive rate while keeping the false positive rate under 20%.
Conclusions We demonstrate that reliable PSQA failure predictors can be successfully developed based solely on MLC leaf positions. Our FT-Transformer neural network can reduce the need for patient rescheduling due to PSQA failures by 80% while sending only 20% of plans that would not have failed the PSQA for replanning. FT-Transformer achieves comparable performance with the leading tree ensemble methods while having an additional benefit of providing an end-to-end differentiable map from MLC leaf positions to the probability of PSQA failure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the University of Washington
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of the University of Washington (STUDY00015736)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* This paper was written prior to the author joining Amazon
Data Availability
The data used in the study is not publicly available